IMM-0306
As of the edition of 20 October 2026, IMM-0306 is a drug: in active development; acts on CD47 and MS4A1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Unknown
- Registered trials
- 6, 0 stopped early
- Disease areas
- Immune system; Blood and lymph; Cancer; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 0 |
| Phase 2 | 3 | 0 | 1 | 0 |
| Phase 3 | 2 | 0 | 2 | 0 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| ImmuneOnco Biopharmaceuticals | Lead sponsor of trials | 2020 to now |
| ImmuneCare Biopharmaceuticals | Lead sponsor of trials | 2024 to now |